Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% – an observational switch study

Código QR

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% – an observational switch study

Sarita S Deshpande,1 Sriram Sonty,1,2 Afzal Ahmad1 1Glaucoma Section, Midwest Eye Center, Calumet City, 2Glaucoma Section, Department of Ophthalmology, University of Illinois at Chicago, Chicago, IL, USA Purpose: The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering effi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Deshpande SS, Sonty S, Ahmad A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	bimatoprost open-angle glaucoma hyperemia Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/cb4147d332704aee8185faf227b4930b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Stevens A, et al.
Publicado: (2016)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf S, et al.
Publicado: (2016)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen J, et al.
Publicado: (2017)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Abayomi B Ogundele, et al.
Publicado: (2010)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat LE, et al.
Publicado: (2016)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin J-E, et al.
Publicado: (2011)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers JS, et al.
Publicado: (2014)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee D, et al.
Publicado: (2017)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Moataz E Gheith, et al.
Publicado: (2008)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2014)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura T, et al.
Publicado: (2012)

Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon
por: Shen J, et al.
Publicado: (2016)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
por: Abayomi B Ogundele, et al.
Publicado: (2010)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee A, et al.
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

The Effect of Brimonidine 0.1% on Disc Hemorrhage in Primary Open-Angle Glaucoma Patients
por: Nitta K, et al.
Publicado: (2020)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Laube T, et al.
Publicado: (2012)

Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
por: Higashiyama T, et al.
Publicado: (2018)

Analysis of Bimatoprost-Induced changes on Rabbits eyelash Follicle: Clinical and Electron microscopic study
por: Sayed KM, et al.
Publicado: (2019)

Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension
por: Tamçelik N, et al.
Publicado: (2017)

An observational study of bimatoprost 0.01% in treatment-na&iuml;ve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
por: Nixon DR, et al.
Publicado: (2012)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober D, et al.
Publicado: (2015)

Effects of different sleeping positions on intraocular pressure in secondary open-angle glaucoma and glaucoma suspect patients
por: Sedgewick JH, et al.
Publicado: (2018)

An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan® RC Early Analysis Review (CLEAR) trial
por: Crichton AC, et al.
Publicado: (2014)

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
por: Wirta D, et al.
Publicado: (2011)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
por: Campbell JH, et al.
Publicado: (2014)

Comparison of Medical Comorbidity between Patients with Normal-Tension Glaucoma and Primary Open-Angle Glaucoma: A Population-Based Study in Taiwan
por: Wei-Yang Lu, et al.
Publicado: (2021)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
por: E Randy Craven, et al.
Publicado: (2010)

The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
por: Hiromitsu Onoe, et al.
Publicado: (2021)

Comparison of ab externo trabeculotomy in primary open-angle glaucoma and uveitic glaucoma: long-term outcomes
por: William A, et al.
Publicado: (2016)

360° ab-interno trabeculotomy in refractory primary open-angle glaucoma
por: Sarkisian SR, et al.
Publicado: (2019)

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
por: Economou MA, et al.
Publicado: (2018)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis VM, et al.
Publicado: (2018)

Outcomes of Phaco-viscocanalostomy in Primary Open Angle Glaucoma versus Pseudoexfoliation Glaucoma
por: Ebrahim Azaripour, et al.
Publicado: (2021)

Canaloplasty and Trabeculotomy Combined with Phacoemulsification in Open-Angle Glaucoma: Interim Results from the GEMINI Study
por: Gallardo MJ, et al.
Publicado: (2021)

No differences in central corneal thickness between open-angle and pseudoexfoliation glaucoma patients
por: Ayala M, et al.
Publicado: (2017)

Success of Primary Trabeculectomy in Advanced Open Angle Glaucoma
por: Pantalon A, et al.
Publicado: (2021)

Clinical evaluation of a trabecular microbypass stent with phacoemulsification in patients with open-angle glaucoma and cataract
por: Ferguson TJ, et al.
Publicado: (2016)

Clinical Results of Ab Interno Canaloplasty in Patients with Open-Angle Glaucoma
por: Hughes T, et al.
Publicado: (2020)